 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS
finance.yahoo.com - November 22 at 9:41 AM |
 | Lixte Biotechnology (NASDAQ:LIXT) Trading Down 3.9%
americanbankingnews.com - November 18 at 12:56 AM |
| Lixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28
finance.yahoo.com - October 20 at 3:20 PM |
| Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment
finance.yahoo.com - October 13 at 9:47 AM |
 | Bullish insiders at Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) loaded up on US$1.3m of stock earlier this year
nasdaq.com - September 26 at 1:01 PM |
| We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth
finance.yahoo.com - September 24 at 1:41 PM |
| Lixte Biotechnology Holdings Inc Shares Fall 1.5% Below Previous 52-Week Low - Market Mover
nasdaq.com - September 22 at 9:49 AM |
| Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction
finance.yahoo.com - August 17 at 5:00 PM |
| Lixte's LB-100 Blocks Behavioral Sensitization In Animal Models
finance.yahoo.com - August 17 at 5:00 PM |
 | Lixte Biotechnology Holdings Inc.
barrons.com - August 8 at 11:44 PM |
|
 | Lixte Biotechnology Shares Are Trading Higher On Encouraging Preclinical LB-100 Data In Lung Cancer
msn.com - August 3 at 4:10 PM |
 | Lixte Biotechnology Shares Rise 31% on Positive Data for Lung Cancer Treatment
marketwatch.com - August 3 at 4:10 PM |
| LIXTE BIOTECHNOLOGY’S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY
finance.yahoo.com - August 3 at 11:10 AM |
| LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM
finance.yahoo.com - July 22 at 12:52 PM |
| Lixte Biotechnology Comments on Outside Research Citing LB-100’s PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer
finance.yahoo.com - July 13 at 1:37 PM |
| Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021
finance.yahoo.com - July 7 at 9:44 AM |
| Companies Like Lixte Biotechnology Holdings (NASDAQ:LIXT) Are In A Position To Invest In Growth
nasdaq.com - June 28 at 12:33 PM |
| Need To Know: Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Insiders Have Been Buying Shares
finance.yahoo.com - June 26 at 1:11 PM |
 | A Breakthrough in Targeted Cancer Therapy: Lixte Biotechnology Clinical Stage Compound LB-100
benzinga.com - June 3 at 9:54 AM |
| Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer
finance.yahoo.com - June 2 at 1:19 PM |
| Santa Monica Partners Lp Buys Boeing Co, Lixte Biotech Holdings Inc
ca.finance.yahoo.com - May 19 at 11:49 PM |
| LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS
finance.yahoo.com - May 12 at 1:09 PM |
| Protein Phosphatase 2A Market Size 2021: Impact of Covid-19, Top Manufacturers, Regional Outlook, Competitive Strategies and Forecasts 2027
marketwatch.com - May 8 at 8:26 AM |
| Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20
finance.yahoo.com - May 4 at 8:31 PM |
| Lixte Biotechnology to Discuss Pipeline of Clinical Investigations for Four Cancer Targets at the Benzinga Global Small Cap Conference Being Held May 13-14
finance.yahoo.com - April 28 at 9:43 AM |
| Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24
finance.yahoo.com - March 17 at 12:48 PM |
 | Lixte Jumps on Direct Offering
baystreet.ca - March 15 at 1:34 PM |
| Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference
finance.yahoo.com - March 3 at 12:47 PM |
 | Guardion Health Sciences Inc Registered Shs Stock , GHSI
markets.businessinsider.com - March 3 at 2:46 AM |
| Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering
finance.yahoo.com - March 2 at 11:44 AM |
| Lixte Biotechnology Announces $4.19 Million Registered Direct Offering
finance.yahoo.com - March 1 at 12:43 PM |
| Lixte Biotech shares are trading higher. Not seeing any company-specific news to justify the price action.
benzinga.com - February 28 at 2:57 PM |
|
| Are These The Top Biotech Stocks To Buy In March? 4 Names To Consider
nasdaq.com - February 26 at 7:57 PM |
| Stock Alert: Lixte Biotechnology Up 55%
markets.businessinsider.com - February 26 at 2:56 PM |
| We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Needs To Drive Business Growth Carefully
finance.yahoo.com - February 25 at 12:47 PM |
| Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - February 24 at 9:49 AM |
 | Lixte Biotech's lead candidate to be tested in small cell lung cancer patients
seekingalpha.com - January 27 at 6:37 PM |
| Stock Alert: Lixte Biotechnology Adds 15% Following Deal With City Of Hope
nasdaq.com - January 19 at 6:56 PM |
 | Lixte Biotechnology Holdings Inc
bloomberg.com - December 23 at 8:48 PM |
| Lixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors
finance.yahoo.com - December 23 at 10:48 AM |
| Lixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical Officer
finance.yahoo.com - December 23 at 10:48 AM |
| The Foundation for Angelman Syndrome Therapeutics (FAST) and Lixte Biotechnology Collaborate to Support the Preclinical Study of Lixte’s Protein Phosphatase 2A Inhibitor, LB-100, as a Possible Treatment for Angelman Syndrome
finance.yahoo.com - December 23 at 10:48 AM |
| Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split
finance.yahoo.com - December 23 at 10:48 AM |
| WestPark Capital Announces Closing of $5,700,000 Follow-On Offering and NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT, LIXTW)
finance.yahoo.com - December 23 at 10:48 AM |
| Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq
finance.yahoo.com - December 23 at 10:48 AM |
| WallachBeth Capital Announces Completion of $5.7 Million Joint Underwritten Public Offering for Lixte Biotechnology Holdings, Inc.
finance.yahoo.com - December 23 at 10:48 AM |
| Lixte Biotechnology's LB-100 to be Evaluated by the National Cancer Institute in a Clinical Study of LB-100's Ability to Enter Recurrent Glioblastoma Multiforme Brain Tumors
finance.yahoo.com - March 16 at 9:50 AM |
| Lixte Biotechnology’s PP2A Inhibitor, LB-100, Improves Brain Function and Motor Impairment in a Mouse Model of Angelman Syndrome, a Rare Human Neurodevelopmental Disorder
finance.yahoo.com - March 16 at 9:50 AM |
| First Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology’s LB-100 in Low or Intermediate-1 Risk Myelodysplastic Syndrome
finance.yahoo.com - March 16 at 9:50 AM |
| The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings’ LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas
finance.yahoo.com - March 16 at 9:50 AM |
